A new report published by the ABPI and Vermilion Life Sciences this week identifies a number of stakeholder issues and proposed actions for the UK in reengineering medicines development.
Reengineering medicines development: Summary output of a stakeholder roundtable on cost-effective development of affordable innovative medicines is the output of a roundtable event on reengineering medicines development held on 4 March which reviewed proposals from
Reengineering medicines development: A stakeholder discussion document for cost-effective development of affordable innovative medicines. Multiple stakeholders including regulatory agencies, Health Technology Assessment (HTA) bodies, patient groups, clinicians, academia and pharmaceutical companies discussed challenges in affordability and duration of medicines development, that lead to delays in access due to cost-effectiveness concerns, and ways to overcome these.
The post-event report recognises that the UK, as part of Europe, is a key player in global development and can play an influential role in developing and adopting novel approaches towards a more sustainable model of medicines development. The opportunity exists to leverage technology that streamlines data collection and its use, build stakeholder partnerships based on greater mutual understanding, and utilise adaptive designs rather than solely relying on randomised controlled trials (RCTs) in order to address the existing challenges.
The roundtable discussion topics included: the use of real world data for regulatory submission; facilitating HTA prediction of value; creating a collaborative environment to support research; improving patient influence on clinical research; and developing better integrated health data to support clinical research.
The ABPI and Vermilion Life Science’s work on reengineering medicines development builds on research carried out by the ABPI on the development and delivery of stratified medicines in the UK and links to the theme of the affordability conundrum, being discussed at the ABPI Annual Conference on 23 April.
Vermilion Life Sciences works to Reengineer Medicines Development to reduce development times and costs, speed adoption of new technologies and improve the value of new medicines. Facilitating partnerships between patients, industry, regulators and payers can make medicines available more quickly, at lower cost with greater certainty in use.
We consult on strategic portfolio reviews, clinical strategies and organisational design to enable sponsors to improve their development efficiency and effectiveness.
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press OfficeTelephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811Email: email@example.com